ADAMTS like 4Genealiases: ADAMTSL-4 · ECTOL2 · TSRC1
Q-omics provides the consensus-scored ADAMTSL4 profile across patient tissues and cancer cell-line models. ADAMTSL4 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ADAMTSL4 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, ADAMTSL4 protein abundance shows 20,969 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, and LSCC as cancer lineages where ADAMTSL4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ADAMTSL4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ADAMTSL4 survival associations across molecular data types. ADAMTSL4 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ADAMTSL4 RNA expression–survival associations across cancer types. High ADAMTSL4 expression shows unfavorable associations in KIRC, LUSC, LGG, READ and OV, but favorable associations in ESCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ADAMTSL4 RNA expression.
This table summarizes ADAMTSL4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ADAMTSL4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ADAMTSL4 shows lower tumor expression in BLCA, LUAD, COAD, BRCA and LUSC and higher tumor expression in KIRC. The KIRC box plot shows higher ADAMTSL4 RNA expression in tumor versus normal tissue (log2 FC = +1.744, t-test p < 0.001).
This table shows molecular features associated with ADAMTSL4 in patient tissues and cancer cell lines. In patient samples, ADAMTSL4 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ADAMTSL4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
